Drug Search Results
More Filters [+]

Teneligliptin

Alternative Names: teneligliptin, mp-513, mp513, mp 513
Latest Update: 2024-06-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | India | Italy | Japan | Korea | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Teneligliptin

Countries in Clinic: Korea

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TERA 304

P3

Recruiting

Type 2 Diabetes

2024-11-01

TERA 305

P3

Recruiting

Type 2 Diabetes

2024-11-01

Recent News Events